Introduction
Cyclosporine is a lipophilic cyclic peptide of 11 amino acids, while tacrolimus is a macrolide antibiotic. Both . Calcineurin inhibitor nephrotoxicity includes acuteazotemia, chronic progressive renal disease, and tubular dysfunction. Although renal insufficiency induced by calcineurin inhibitors has received the most attention, tubular dysfunctions are also clinically important and will be briefly reviewed in this article.
Calcineurin inhibitor-associated tubular dysfunction is manifested by metabolic acidosis, hyperkalemia, calcium, phosphate wasting, and magnesium loss.
Metabolic acidosis
Metabolic acidosis is common in patients with kidney transplantation. The first case report with post-transplant renal tubular acidosis was described by Massry et al. almost three decades ago 2) . Renal tubular acidosis (RTA) is non-anion gap metabolic acidosis and is generally mild and a symptomatic in kidney recipients 3) .
The reported prevalence of calcineurin inhibitor-associated RTA is 13-17% intransplanted patients [4] [5] [6] .
Calcineurin inhibitor-associated RTA can be both Nephrotoxicity is the most common and clinically significant adverse effect of calcineurin inhibitors.
Cyclosporine and tacrolimus nephrotoxicity is manifested by both acute azotemia and chronic progressive renal disease and tubular zdysfunction. An elevation in the plasma potassium concentration due to reduced efficiency of urinary potassium excretion is common in cyclosporine-treated patients; it may be severe and potentially life-threatening with concurrent administration of an angiotensin converting enzyme inhibitor, which diminishes aldosterone release. Tubular injury induced by cyclosporine can also impair acid excretion. This may be presented as a hyperchloremic metabolic acidosis associated with decreased aldosterone activity and suppression of ammonium excretion by hyperkalemia. Some patients treated with cyclosporine develop hypophosphatemia due to urinary phosphate wasting. Renal magnesium wasting is also common presumably due to drug effects on magnesium reabsorption. Hypomagnesemia has also been implicated as a contributor to the nephrotoxicity associated with cyclosporine. Both cyclosporine and tacrolimus are associated with hypercalciuria. Attention must be paid to drug dose, side effects, and drug interactions to minimize toxicity and maximize efficacy. There are some reports now that provide some insight as to how that might occur. Collecting ducts have 2 types of intercalated cells -the acid or hydrogen ionsecreting alpha-intercalated cells and the bicarbonatesecreting beta-intercalated cells (Fig. 1) . The preponderance of which cell dominates rests on the type of diet.
An acid diet leads to more alpha-intercalated cells, Treatment of calcineurin inhibitor-associated acidosis is mainly with oral supplement of bicarbonate 4, 12) .
Synthetic mineralo corticoid is apotential treatment option, but has more frequent side effects 10) .
Hyperkalemia is a recognized complication of cyclosporine and tacrolimus. Reported incidence of hyperkalemia is 5-40% among calcineurin inhibitortreated patients 13, 14) .
An elevation in plasma potassium concentration due to reduced efficiency of urinary potassium excretion is common in calcineurin inhibitor-treated patients. It may be severe and potentially life-threatening with concurrent administration of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker.
Cyclosporine may reduce potassium excretion by altering the function of several transporters, decreasing the activity of the renin-angiotensin-aldosterone system, and impairing tubular responsiveness to aldosterone 15, 16) .
Renal potassium excretion is primarily derived from . Hydration and a low-potassium diet are preferred during that period. [25] [26] [27] . Hypomagnesemia has also been implicated as a contributor to the nephrotoxicity associated with cyclosporine 28) .
It is known that cyclosporine treatment induces high bone-turnover osteopenia and hypercalciuria. Both cy- 
